Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (71-80 of 349) with videos related to

Pageof 35
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 19, 2011
TrkB as a potential synaptic and behavioral tagYuan Lu, Yuanyuan Ji, Sundar Ganesan, et al.
Clinical Lung Cancer|January 27, 2019
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase InhibitorJiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasisSeonggyu Byeon, Jun Soo Ham, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
Biology|October 10, 2020
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 14, 2023
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World DataYoungkyung Jeon, Sehhoon Park, Hyun Ae Jung, et al.
Cancer Research and Treatment|October 13, 2022
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain MetastasisHongsik Kim, Sehhoon Park, Hyun Ae Jung, et al.
Oncology|November 13, 2010
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatmentSeung Tae Kim, Jeeyun Lee, Jong-Mu Sun, et al.
Pageof 35

Showing results (71-80 of 349) with videos related to

Sort By:
Pageof 35
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 19, 2011
TrkB as a potential synaptic and behavioral tagYuan Lu, Yuanyuan Ji, Sundar Ganesan, et al.
Clinical Lung Cancer|January 27, 2019
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase InhibitorJiyun Lee, Jong-Mu Sun, Se-Hoon Lee, et al.
Medical Oncology (Northwood, London, England)|July 23, 2016
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasisSeonggyu Byeon, Jun Soo Ham, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 27, 2019
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in KoreaKangkook Lee, Hyun Ae Jung, Jong-Mu Sun, et al.
Translational Lung Cancer Research|March 15, 2021
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitorsHongsik Kim, Hyun Ae Jung, Se-Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 17, 2024
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysisHyun Ae Jung, Boram Park, Sehhoon Park, et al.
Biology|October 10, 2020
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, et al.
Cancer Research and Treatment|July 14, 2023
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World DataYoungkyung Jeon, Sehhoon Park, Hyun Ae Jung, et al.
Cancer Research and Treatment|October 13, 2022
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain MetastasisHongsik Kim, Sehhoon Park, Hyun Ae Jung, et al.
Oncology|November 13, 2010
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatmentSeung Tae Kim, Jeeyun Lee, Jong-Mu Sun, et al.
Pageof 35